Development of highly stable galectins: Truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins  by Nishi, Nozomu et al.
FEBS Letters 579 (2005) 2058–2064 FEBS 29403Development of highly stable galectins: Truncation of the linker
peptide confers protease-resistance on tandem-repeat type galectins
Nozomu Nishia,*, Aiko Itohb, Aimi Fujiyamab, Naoko Yoshidab, Shin-ichi Arayab,
Mitsuomi Hirashimac, Hiroki Shojia, Takanori Nakamuraa
a Department of Endocrinology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan
b GalPharma Co., Ltd., 2217-44 Hayashimachi, Takamatsu, Kagawa 761-0301, Japan
c Department of Immunology and Immunopathology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho,
Kita-gun, Kagawa 761-0793, Japan
Received 28 December 2004; revised 26 January 2005; accepted 20 February 2005
Available online 10 March 2005
Edited by Masayuki MiyasakaAbstract Galectin-9 and galectin-8, members of b-galactoside-
binding animal lectin family, are promising agents for the treat-
ment of immune-related and neoplastic diseases. The proteins
consist of two carbohydrate recognition domains joined by a lin-
ker peptide, which is highly susceptible to proteolysis. To in-
crease protease resistance, we prepared mutant proteins by
serial truncation of the linker peptide. As a result, mutant forms
lacking the entire linker peptide were found to be highly stable
against proteolysis and retained their biological activities. These
mutant proteins might be useful tools for analyzing the biological
functions and evaluating the therapeutic potential of galectin-9
and galectin-8.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Galectins constitute a family of soluble animal lectins that
are deﬁned based on their aﬃnity for b-galactosides and their
conserved sequence elements. To date, 10 members of the hu-
man galectin family are known. The members can be classiﬁed
into three subtypes according to their structures. The proto-
type (galectin-1, -2, -7, -10 and -13) and chimera-type (galec-
tin-3) galectins have a single carbohydrate recognition domain
(CRD), and they usually form a non-covalent homodimer
resulting in homobifunctional sugar-binding activity. While
tandem-repeat-type galectins (galectin-4, -8, -9, and -12) have
two CRDs, which generally show diﬀerent sugar-binding spec-
iﬁcities, joined by a linker peptide. This heterobifunctional
property makes them capable of crosslinking a wide variety
and combinations of glycoconjugates. Tandem-repeat-type
galectins, however, are more susceptible to proteolysis than
other galectins due to the presence of the relatively long linker
peptide.Abbreviations: CRD, carbohydrate recognition domain; GST, gluta-
thione S-transferase; MMP-3, matrix metalloproteinase-3; ECA, eos-
inophil chemoattractant
*Corresponding author. Fax: +81 87 891 2108.
E-mail address: nnishi@med.kagawa-u.ac.jp (N. Nishi).
0014-5793/$30.00  2005 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2005.02.054Human galectin-9 was ﬁrst identiﬁed as a novel tumor anti-
gen of unknown function in patients with Hodgkins disease
[1]. Recent studies suggested that galectin-9 is a novel type of
modulator of immune functions: galectin-9 has been shown
to induce chemotaxis of eosinophils [2] and apoptosis of acti-
vated but not resting T lymphocytes [3,4]. Up-regulation of
galectin-9 gene expression by interferon-c [5] and synthetic
double-stranded RNA (poly IC) [6] in human endothelial cells
is consistent with this idea. In addition, galectin-9 induces the
apoptosis of a wide variety of tumor cells much more eﬃciently
than other family members [3]. Although these ﬁndings indi-
cate that galectin-9 is a promising agent for the treatment of
immune-related and neoplastic diseases, the protease suscepti-
bility of the protein makes it diﬃcult to eﬃciently carry out in
vivo experiments with recombinant proteins. Here, we report
development of protease resistant galectin-9 and galectin-8, a
modulator of neutrophil function [7], by modiﬁcation of their
linker peptides.2. Materials and methods
2.1. Construction of expression vectors
The following forward (F) and reverse (R) primers (Fig. 1) were used
to amplify cDNAs for the wild-type and mutant galectins from plas-
mids containing the respective cDNA [8]:
G9NF1e (5 0-CGTCCTCATATGGCCTTCAGCGGTTCCCAG-3 0),
G9NF1g (5 0-CGTCCTGAATTCCCATGGCCTTCAGCGGTTCC-
CAG-3 0),
G9NR1e (5 0-CGACCGCATATGCTGGAAGCTGATGTAGGAC-
AG-3 0),
G9NR1g (5 0-CGACCGCTCGAGCTACTGGAAGCTGATGTAG-
GACAG-30),
G9NR2 (5 0-CGACCGCATATGGTGGATGACTGTCTGGGTC-
TG-3 0),
G9NR3 (5 0-CGACCGCTCGAGCTAAGAGCCATTGACGGAGA-
TGGT-3 0),
G9CF1e (5 0-CGTCCTCATATGACTCCCGCCATCCCACCTATG-
3 0),
G9CF1g (5 0-CGTCCTGAATTCCCACTCCCGCCATCCCACCTA-
TG-3 0),
G9CF2e (5 0-CGTCCTCATATGATGATGTACCCCCACCCCGCC-
3 0),
G9CF2g (5 0-CGTCCTGAATTCCCATGATGTACCCCCACCCC-
GCC-3 0),
G9CF3e (5 0-CGTCCTCATATGGCCTATCCGATGCCTTTCATC-
3 0),
G9CF3g (5 0-CGTCCTGAATTCCCGCCTATCCGATGCCTTTCA-
TC-3 0),blished by Elsevier B.V. All rights reserved.
Fig. 1. Schematic representation of the primer sites used for ampliﬁcation of galectin-9 and galectin-8 cDNAs. As it is not easy to unequivocally
determine the linker peptide region without three-dimensional structural data, the assignment should be considered as provisional (see footnote of
Table 1). Galectin-9S, a wild-type isoform of galectin-9 with the shortest linker peptide. Galectin-8M, a wild-type isoform of galectin-8 with a short
linker peptide.
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TCC-30),
G9CF5 (5 0-CGTCCTCATATGCCTGGACAGATGTTCTCTACT-
3 0),
G9CR1e1 (5 0-CGACCGAGATCTCTATGTCTGCACATGGGTC-
AG-3 0),
G9CR1e2 (5 0-CGACCGGGATCCCTATGTCTGCACATGGGTC-
AG-3 0),
G9CR1g (5 0-CGACCGCTCGAGCTATGTCTGCACATGGGTC-
AG-3 0),
G8NF1 (5 0-CGTCCTCATATGATGTTGTCCTTAAACAACCTA-
3 0),
G8NR1 (5 0-CGACCGCATATGCGAGCTGAAGCTAAAACCA-
AT-3 0),
G8CF1 (5 0-CGTCCTCATATGAGGCTGCCATTCGCTGCAAGG-
3 0),
G8CR1 (5 0-CGACCGAGATCTCTACCAGCTCCTTACTTCCAG-
3 0),
G8CR2 (5 0-CGACCGGGATCCCTACCAGCTCCTTACTTCCAG-
3 0).
Expression vectors for tag-free wild-type galectins were prepared as
follows: full-length cDNAs were ampliﬁed using G9NF1e + G9CR1e1
(galectin-9) and G8NF1 + G8CR1 (galectin-8). Ampliﬁed cDNAs
were digested with NdeI and BglII, and then inserted into the NdeI–
BamHI site of pET-11a (Stratagene). In the case of mutant galectins,
cDNAs coding for diﬀerent types of C-terminal CRDs were ampliﬁed
using G9CF1e/G9CF2e/G9CF3e/G9CF5 + G9CR1e2 and G8CF1 +
G8CR2, digested with NdeI and BamHI, and then inserted into the
NdeI–BamHI site of pET-11a. The resulting plasmids were designated
as pET-G9C/-G9C(-6)/-G9C(-12)/-G9C(+6) and pET-G8C. The plas-
mids were digested with NdeI and then dephosphorylated. A cDNA
coding for the N-terminal CRD was ampliﬁed using G9NF1e +
G9NR1e and G8NF1 + G8NR1, digested with NdeI, and then inserted
into the dephosphorylated plasmids. The resulting plasmids, coding for
galectin-9 mutants consisting of a wild-type N-terminal CRD and dif-
ferent types of C-terminal CRDs, were designated as pET-G9Null/-G9
Null(-C6)/-G9 Null(-C12)/-G9 Null(LC6). The cDNA ampliﬁed using
G9NF1e + G9NR2 was digested with NdeI, and then inserted into
dephosphorylated pET-G9C. The resulting plasmid was designated
as pET-G9Null (LN6).
Expression vectors for glutathione S-transferase (GST)-fusion pro-
teins were prepared as follows: cDNAs coding for diﬀerent types of
N- and C-terminal CRDs were ampliﬁed using G9NF1g + G9NR1g/
G9NR3 and G9CF1g/G9CF2g/G9CF3g/G9CF4 + G9CR1g, digested
with EcoRI and XhoI, and then inserted into the EcoRI–XhoI site of
pGEX-4T-2 (Amersham Biosciences). The DNA sequences of all the
expression vectors were conﬁrmed by automated sequencing.
2.2. Expression and puriﬁcation of recombinant proteins
Expression of GST-fusion proteins in Escherichia coli (E. coli)
BL21 cells was carried out as described previously [8]. Recombinant
proteins were puriﬁed by aﬃnity chromatography on a lactose–aga-
rose column (Seikagaku Corp., Tokyo, Japan) and/or a glutathi-
one–sepharose column (Amersham Biosciences). Tag-free proteins
(pET vector) were expressed by essentially the same method as that
for GST-fusion proteins except that E. coli BL21(DE3) cells were
used. Tag-free proteins were puriﬁed by aﬃnity chromatography ona lactose–agarose column. The protein concentration was determined
using BCA protein assay reagent (Pierce) and bovine serum albumin
as a standard.2.3. Protease treatment
Tag-free recombinant proteins were ﬁrst incubated at 37 C for
5 min in digestion buﬀer. After the addition of a protease, the reaction
mixture was incubated for 120 min at 37 C. The total reaction mix-
ture, 600 ll, contained 36 lg of protein sample with an enzyme to sub-
strate ratio of 1:100 (weight ratio). Aliquots were withdrawn from the
reaction mixture at diﬀerent times for sodium dodecyl sulphate–poly-
acrylamide gel electrophoresis (SDS–PAGE). The following digestion
buﬀers were used for trypsin/elastase and matrix metalloproteinase-3
(MMP-3), respectively: 0.1 M Tris–HCl (pH 8.0), 0.15 M NaCl,
1 mM CaCl2, and 0.05 M Tris–HCl (pH 7.5), 0.15 M NaCl, 10 mM
CaCl2, 1 lM ZnCl2. Activated MMP-3 was prepared as described pre-
viously [7].2.4. In vitro biological activities
2.4.1. Chemotaxis. Eosinophil chemoattractant (ECA) activity was
evaluated in vitro [2]. Eosinophils were enriched by applying peripheral
blood leukocytes to a discontinuous density gradient of Percoll (Amer-
sham Biosciences). ECA activity was evaluated using a 48-well cham-
ber (Neuro Probe Inc.). Human eosinophils (0.5–1 · 106/ml) and
various concentrations of a test sample were placed in the top and bot-
tom chambers, respectively. Each assay was performed in triplicate.
After 1- to 2-h incubation at 37 C, the membrane separating the
two chambers was removed and placed in Diﬀ-Quick stain (Baxter
Healthcare Corp.). Stained eosinophils were counted under a micro-
scope. Human eotaxin-1 (Seikagaku Corp.) was used as a control.
2.4.2. Apoptosis. Apoptosis-inducing activity was assessed using
MOLT-4 cells [3]. Cultured cells were incubated with an assay sample
for 24 h. The cells were recovered by centrifugation, and then resus-
pended in 300 ll of PBS and 700 ll of 100% ethanol. The cells were
washed with PBS, and then incubated with 50 lg/ml ribonuclease A
for 30 min at 37 C, followed by with 50 lg/ml of propidium iodide
for 10 min. Stained cells were analyzed by ﬂow cytometry.
2.4.3. Cell proliferation. The antiproliferative eﬀect on a human
prostatic cancer cell line (PC-3) was determined by means of the
WST-8 assay. PC-3 cells (3 · 103 cells in 100 ll) were plated in 96-well
plates and then cultured for 48 h. Test samples were added at various
concentrations, and the culture was continued for 24 h. WST-8 reagent
(Cell counting kit-8; Dojin Laboratories, Kumamoto, Japan) was
added to the cells (10 ll/well), followed by incubation for 2 h. Each as-
say was performed in triplicate. Using an enzyme-linked immunoad-
sorbent assay autoreader, the viable cell number was determined by
measuring the diﬀerence between the absorbance at 450 and that of
620 nm.
2.4.4. Neutrophil adhesion. The neutrophil adhesion assay was car-
ried out as described previously [7]. Isolated cells were added to 24-well
tissue culture plates (2.5 · 105 cells in 0.45 ml of medium/well) in trip-
licate. After the addition of 50 ll of the assay sample, the cells were al-
lowed to adhere for 60 min at 37 C. At the end of the incubation
period, loosely attached cells were removed by pipetting. The attached
cells were recovered by treatment with trypsin/EDTA, and then soni-
cated. The DNA content of the sonicate was determined.
2060 N. Nishi et al. / FEBS Letters 579 (2005) 2058–20643. Results and discussion
3.1. Assignment of the linker peptide
In the present study, the N- and C-terminal CRDs and a
linker peptide region were tentatively assigned (Fig. 1) based
on the intron–exon structures of the galectin-9 and -8 genes
[9,10]. However, X-ray crystallographic data for proto-type
and chimera-type galectins predict that sequences ﬂanking
the linker peptide region may not constitute tightly folded
CRDs [11]. To identify the sequences that are dispensable
for the sugar-binding activity of galectin-9 CRDs, several
truncation mutants were expressed and their aﬃnity for lac-
tose was tested. GST-fusion proteins of the N- and C-termi-
nal CRDs (GST-G9NCRD and GST-G9CCRD) were
expressed in E. coli and could be aﬃnity puriﬁed with lac-
tose–agarose gel, although signiﬁcant parts of these fusion
proteins were not retained by the gel (Fig. 2, lane 3 vs. lane
4). The solubility of GST-G9NCRD decreased on truncation
of the C-terminal 9 amino acids, which may constitute the
most C-terminal b-sheet of G9NCRD [12,13]; only a negligi-
ble amount of the fusion protein, GST-G9NCRD(-9), could
be solubilized and the solubilized fraction did not show any
aﬃnity for lactose. On the other hand, truncation of theFig. 2. Puriﬁcation proﬁles of GST-fusion proteins on SDS–PAGE. The wil
fusion proteins, and then puriﬁed by lactose-aﬃnity chromatography and g
were electrophoretically separated in a SDS/12% polyacrylamide gel under red
M, molecular weight markers; lane 1, E. coli BL21 cell lysate; lane 2, E. coli BL
lane 4, eluate from glutathione–sepharose (the ﬂow-through fraction from la
Table 1
Structures of the wild-type and mutant forms of galectin-9
Protein name N-terminal CRD
G9M Met1–Gln148
G9S Met1–Gln148
(S-type linker peptide
G9Null Met1–Gln148
G9Null(LN6) Met1–Gln148
G9Null(LC6) Met1–Gln148
G9Null(-C6) Met1–Gln148
G9Null(-C12) Met1–Gln148
Superscript numbers for mutant forms indicate amino acid positions in G9S
peptide regions of mutant forms are shown in a one-letter code. His–Met/HM
NdeI sites (CATATG) of the respective expression vectors. In the present s
tentatively assigned as shown in Fig. 1. However, X-ray crystallographic s
Met181–Thr311 form stably folded cores of N-CRD and C-CRD, respectively.
residues Thr149–Pro177/Pro180 (TQTVIHTVQSAPGQMFSTPAIPPMMYPHN-terminal 6 and 12 amino acids hardly aﬀected the lac-
tose-binding activity of G9CCRD (GST-G9CCRD(-6) and
GST-G9CCRD(-12)). Further truncation of 10 amino acids,
which may constitute the most N-terminal b-sheet of
G9CCRD, resulted in almost complete inhibition of expres-
sion of the protein, GST-G9CCRD(-22). These results
suggest that the removal of at least 12 amino acids of the
N-terminal portion of G9CCRD in addition to the linker
peptide may not aﬀect the sugar-binding activity of galec-
tin-9, although quantitative data are lacking.3.2. Protease susceptibility of the wild type and mutant forms of
galectin-9
We prepared a series of mutant forms of galectin-9 lacking
diﬀerent parts of the linker peptide and the N-terminal re-
gion of G9CCRD based on the data given in the previous
section (Table 1). These proteins were successfully expressed
as tag-free forms and puriﬁed with lactose–agarose, and then
their susceptibilities to extracellular proteases were compared
with that of wild-type galectin-9. Two isoforms of wild-type
galectin-9, G9S and G9M, were almost completely degraded
by MMP-3/stromelysin within 2 h at 37 C and an enzyme tod-type and mutant forms of galectin-9 CRDs were expressed as GST-
lutathione-aﬃnity chromatography. Samples at each puriﬁcation step
ucing conditions and then stained with Coomassie brilliant blue R-250.
21 crude extract (soluble fraction); lane 3, eluate from lactose–agarose;
ctose–agarose was subjected to glutathione-aﬃnity chromatography).
Linker region C-terminal CRD
Pro149–Ser177 Thr178–Thr323
Thr149–Ser165 Thr166–Thr311
TQTVIHTVQSAPGQMFS)
HM Thr166–Thr311
TQTVIHHM Thr166–Thr311
HMPGQMFS Thr166–Thr311
HM Met172–Thr311
HM Ala178–Thr311
. The amino acid sequences of the S-type linker peptide and the linker
residues in the linker regions of mutant forms are derived from the
tudy, the N- and C-terminal CRDs and a linker peptide region were
tudies and phylogenetic analyses [16] predict that Val15–Gln148 and
Because this prediction agrees closely with the results shown in Fig. 2
P[AYP]) most likely constitute functional linker region of G9S.,
Fig. 3. Protease susceptibility of the wild-type and a mutant form of
galectin-9. (A) Two isoforms of wild-type galectin-9 (G9S and G9M)
and a mutant form lacking the entire linker region (G9Null) were
incubated with MMP-3 or elastase at an enzyme to substrate ratio of
1:100 at 37 C. Aliquots were withdrawn from the reaction mixture at
diﬀerent times and then subjected to SDS–PAGE. The molecular
masses of G9S, G9M and G9Null are 34.7, 35.9 and 33.1 kDa,
respectively. M, molecular weight markers. (B) Integrated intensities of
intact protein bands were determined by densitometric scanning. Data
represent the mean values for two independent experiments.
Fig. 4. Eﬀects of linker peptide and CRD structures on the protease susceptib
the linker peptide, G9Null(LN6) and G9Null(LC6), and ones lacking the entir
and G9Null(-C12), were incubated with MMP-3 or elastase at an enzyme to
reaction mixture at diﬀerent times and subjected to SDS–PAGE. M, molecu
N. Nishi et al. / FEBS Letters 579 (2005) 2058–2064 2061substrate ratio of 1:100 (Fig. 3). G9M was degraded more
rapidly than G9S, which has the shortest linker peptide
among the wild-type isoforms [14]. Elastase was more potent
than MMP-3 as to degradation of G9S and G9M (data for
G9M not shown). The isoforms were hardly degraded by
trypsin under the above conditions, probably due to the ab-
sence of arginine and/or lysine residues in the linker peptide
(data not shown). A mutant form lacking the entire linker
region, G9Null, was completely resistant to both proteases
and trypsin during 2 h incubation. Detailed time course anal-
ysis showed that G9Null is at least 100 times more stable
than G9M against MMP-3 and elastase. G9Null(LN6) and
G9Null(LC6), having the most N-terminal and C-terminal
6 amino acids of the S-type linker peptide, respectively,
showed diﬀerent susceptibilities (Fig. 4). G9Null(LN6) exhib-
ited sensitivity to elastase comparable to that of G9S, but
was resistant to MMP-3. While G9Null(LC6) was degraded
by both proteases with lower sensitivity than in the case of
G9S. Truncation of 6 and 12 amino acids of the N-terminal
region of G9CCRD (G9Null(-C6) and G9Null(-C12)) did
not change the sensitivity of G9Null to MMP-3, but unex-
pectedly resulted in slightly enhanced sensitivity to elastase
(Fig. 4). These results indicate that diﬀerent regions of the
linker peptide exhibit diﬀerent susceptibilities to proteases
and that removal of the entire linker region of galectin-9
greatly improved the stability against proteases. In addition,
it is possible that the N-terminal 12 amino acids of
G9CCRD cause to the structural stability of G9CCRD,
although, the sequence may not be essential for the sugar-
binding activity.
The linker peptides of human tandem-repeat-type galectins
so far identiﬁed comprise at least about 20 amino acid
residues. Whereas some Caenorhabditis elegans galectins
(LEC-1–LEC-4) have a very short linker peptide (less than
5 amino acid residues). These galectins may be more resis-
tant to proteolysis than other C. elegans galectins with the
tandem-repeat type structure. It is possible that they have
relatively long in vivo half-lives and play distinct physiolog-
ical roles.
Lactose-aﬃnity chromatography yields galectin-9 prepara-
tions, both wild type and mutant forms, of high purity. How-
ever, aﬃnity-puriﬁed G9M was degraded during storage at
4 C, possibly due to contaminating bacterial proteases. Theility of galectin-9. Mutant forms of galectin-9 lacking diﬀerent parts of
e linker region and diﬀerent parts of the C-terminal CRD, G9Null(-C6)
substrate ratio of 1:100 at 37 C. Aliquots were withdrawn from the
lar weight markers.
Fig. 6. Comparison of the biological activities of the wild-type and a
mutant form of galectin-9. (A) ECA activity was assessed in vitro by
the chamber method. In the assay, a porous membrane separated the
top chamber containing puriﬁed human eosinophils from the bottom
Fig. 5. Comparison of long-term stability during storage between the
wild-type and a mutant form of galectin-9. Puriﬁed G9M and G9Null
(phosphate buﬀered saline solution) were stored at 4 C under sterile
conditions. Aliquots were withdrawn at diﬀerent times and then
subjected to SDS–PAGE. M, molecular weight markers.
2062 N. Nishi et al. / FEBS Letters 579 (2005) 2058–2064intact G9M molecule completely disappeared within three
weeks of storage at 4 C under sterile conditions (Fig. 5). While
G9Null remained intact for at least 6 months and only a small
amount of degradation products was detectable even after one
year of storage. Because galectin-9 has a tendency to aggregate
upon freeze-thaw treatment, the long-term stability of G9Null
in solution could solve the problems regarding storage of re-
combinant protein.
chamber containing the assay sample. After 1- to 2-h incubation at
37 C, the membrane was removed and stained with Diﬀ-Quick. The
numbers of eosinophils that had migrated through the membrane are
indicated. The results represent the means ± S.D. for three experiments
performed in triplicate. (B) Proapoptotic activity was assessed by
propidium iodide labeling. MOLT-4 cells cultured in the presence of an
assay sample for 24 h were recovered by centrifugation, ﬁxed and then
treated with ribonuclease A. The cells were stained with propidium
iodide and then analyzed by ﬂow cytometry. The results were
expressed as % of total cells. The results represent the means ± S.D.
for three experiments. (C) The antiproliferative eﬀect on PC-3 cells was
determined by means of the WST-8 assay. PC-3 cells were cultured in
the presence of an assay sample for 24 h. After the addition of WST-8
reagent, the culture was continued for 2 h. The viable cell number was
determined with an automated plate reader. The viable cell number of
untreated control culture was taken as 100%. The results represent the
means ± S.D. of triplicate measurements.3.3. Biological activities of G9Null
Galectin-9 has several distinct biological activities, which
depend on the sugar-binding speciﬁcities of the CRDs and
the tandem-repeat type structure of the protein [8,15]. To
determine the eﬀects of removal of the linker peptide on
its biological activities, we compared ECA activity and
apoptosis-inducing activity between wild-type galectin-9
and G9Null. G9M, G9S and G9Null showed maximum
ECA activities that were comparable at 0.3 lM (Fig. 6A).
This ﬁnding is consistent with our previous report showing
that the ECA activity of galectin-9 does not depend on a
speciﬁc structure of the linker peptide [14]. However, G9Null
showed higher activity than that of wild-type galectin-9 at
concentrations lower than 0.3 lM. Apoptosis-inducing activ-
ity was assessed using MOLT-4 human lymphoblastic leuke-
mia cells and PC-3 human prostate tumor cells, although the
mechanism underlying the antiproliferative eﬀect of galectin-9
on PC-3 cells remains obscure (apoptosis or necrosis). G9Null
induced apoptosis of MOLT-4 cells and growth inhibition of
PC-3 cells in dose-dependent manners (Fig. 6B and C). The
eﬀects of G9Null were higher than those of G9M and G9S
at all concentrations tested. G9Null was about two times more
potent than G9M in inducing the apoptosis of MOLT-4 cells
and growth inhibition of PC-3 cells. Western blot analysis re-
vealed that not only G9Null but also G9M and G9S remained
intact during the assay period (data not shown). Therefore,
inactivation of wild-type isoforms by proteolysis in the cell cul-
ture medium is not the reason for these increased biological
activities of G9Null. It is possible that glycoconjugates cross-
linked with G9Null can interact more eﬃciently with eachother than those crosslinked with wild-type galectin-9 depend-
ing on the spatial arrangement of two CRDs, which results in
the increased biological activities of G9Null.3.4. Protease susceptibility and biological activity of galectin-8
lacking the linker peptide
G8Null, a mutant form of galectin-8 lacking the entire lin-
ker region, was prepared by a method analogous to that
used for galectin-9 and was examined as to its susceptibility
to proteases. Wild-type galectin-8, G8M, was almost com-
pletely degraded by trypsin and elastase within 15 min at
37 C (Fig. 7A), but was resistant to MMP-3 (data not
shown). As in the case of galectin-9, removal of the linker
peptide greatly increased the protease resistance of galectin-8.
Fig. 7. Protease susceptibility and neutrophil adhesion-inducing
activity of the wild-type and a mutant form of galectin-8. (A) The
wild-type galectin-8 (G8M) and a mutant form lacking the entire
linker region (G8Null) were incubated with trypsin or elastase at an
enzyme to substrate ratio of 1:100 at 37 C. Aliquots were withdrawn
from the reaction mixture at diﬀerent times and then subjected to
SDS–PAGE. The molecular masses of G8M and G8Null are 35.8
and 33.1 kDa, respectively. M, molecular weight markers. (B)
Neutrophil adhesion-inducing activity was assessed in vitro. Puriﬁed
human neutrophils were plated on tissue culture plates. After the
addition of an assay sample, the cells were allowed to adhere for
60 min at 37 C. The DNA content of the attached cells was
determined. The results represent the means ± S.D. of triplicate
measurements.
N. Nishi et al. / FEBS Letters 579 (2005) 2058–2064 2063About 72% and 94% of G8Null remained intact after 2-h
incubation with trypsin and elastase, respectively. We have
previously reported that galectin-8 modulates the neutro-
phil function (cell adhesion and superoxide production) via
interaction with integrin aM [7]. G8Null induced neutrophil
adhesion in a manner comparable to that in the case of
G8M (Fig. 7B).4. Conclusions
In the present study, we aimed to produce protease-resistant
forms of tandem-repeat-type galectins by modifying the linker
peptide structure. This strategy was based on our previous
observation that three isoforms of galectin-9, which only diﬀer
in the linker peptide structure, exhibit comparable ECA activ-
ity. As expected, removal of the entire linker peptide region of
galectin-9 and galectin-8 greatly improved their stability
against proteolysis without negative eﬀects on their biological
activities. The increased speciﬁc activity of G9Null as to induc-
tion of apoptosis/growth inhibition of tumor cells was an unex-
pected outcome of the modiﬁcation. The mutant forms of
tandem-repeat-type galectins, i.e., G9Null and G8Null, might
be useful agents for evaluating the therapeutic potential of
these proteins. In vivo experiments with several disease models
are currently in progress.
In addition to human galectin-9 and -8, we have prepared a
mutant form of mouse galectin-9 and found that this method
works equally well for the mouse protein (data not shown).
Therefore, this simple and readily applicable method is ex-
pected to be useful for producing protease-resistant forms of
other tandem-repeat-type galectins, namely galectin-4 and
galectin-12 in the case of human galectin family.
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